Abstract

CAR-T CELL THERAPY IN MULTIPLE MYELOMA

Anagha S.* and Manoj Kumar S.

ABSTRACT

A hematologic malignancy known as multiple myeloma (MM) ischaracterized by the clonal proliferation of altered plasma cells. Mostpatients still don't have a cure for multiple myeloma (MM), despitesignificant advancements in the treatment paradigm. But now a notableadvancements in cancer treatment over the past few years havecompletely changed the way cancer patients are cared for. While longestablishedtreatment options for multiple myeloma (MM) includesurgery, chemotherapy, and radiation therapy, a novel therapeuticstrategy known as CAR T-cell therapy has emerged as a game-changer.Using patients' own T cells that have been genetically modified totarget cancer cells, chimeric antigen receptor (CAR)-T-cell therapy hasemerged as the most promising immunotherapy for cancer. Thedifficulties that still need to be overcome, which were discussed in thisarticle, include selecting a suitable combination of treatments andidentifying more effective targets for CAR T-cell therapy. In thisreview, we are going to give a general overview of the scientific and technical elements ofCAR-T cells as well as information on how the therapy works to treat multiple myeloma(MM), how it overcomes resistance patterns, and what happens when CAR-T cell therapyfails. Additionally, the paper examined strategies for expanding the use of car-t cell treatmentin light of impending developments.

Keywords: Multiple myeloma, CAR-T Cell therapy, Immunotherapy, B-cell maturation antigen (BCMA), tumor.